Our
Speakers (A-Z)

Andreas Bernkop-Schnürch

CSO at Thiomatrix Forschungs- Beratungs GmbH

Andreas Bernkop-Schnürch is a leading scientist in the field of drug delivery focusing on mucoadhesive polymers such as in particular thiomers, non-invasive peptide delivery systems and nanoemulsions.

He is chairman at the Department of Pharmaceutical Technology at the University of Innsbruck, Austria and CSO of the drug delivery company ThioMatrix GmbH. He has published more than 500 reseach and review articles.

Audrey Bonestebe

Lab head Drug Product development of Biologics at Sanofi

Audrey Bonestebe is an Industrial process engineer with specialization on pharmaceutical production and control. She has 16 years in pharmaceutical industry mainly in R&D 5 years in Biologics Formulation and DP development

Ekkehard Leberer

Senior Director, R&D Alliance Management at Sanofi

Dr. Ekkehard Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986). His Ph.D. work in molecular biology of muscle development and disease was honoured with the Byk-Price of the Herbert Quandt-Stiftung of the Altana AG for its relevance in pharmaceutical research.

Eva-Maria Knoch

Senior Scientist I at AbbVie

Eva-Maria Knoch is a Senior Scientist in NBE Drug Product Development at AbbVie Ludwigshafen. In 2013 and 2014 she was running her PostDoctoral studies at AbbVie, focused in Drug Product Development, NBE Formulation and Process Sciences. Since June 2014 she is working as a Senior Scientist at AbbVie, focusing in Drug Product Development, NBE Formulation Sciences.

Ijeoma Uchegbu

Chief Scientific Officer at Nanomerics

Ijeoma Uchegbu is Professor of Pharmaceutical Nanoscience at the UCL School of Pharmacy, University College London (UCL), UCL’s Pro-Vice Provost for Africa and The Middle East and Chief Scientific Officer of Nanomerics Ltd. Nanomerics is a UCL spin out company, which was founded by Ijeoma and Andreas G. Schätzlein (http://www.nanomerics.com/).

Isabel Ottinger

Team Head Pharmaceutical Development Early Phase at Novartis Pharma AG

Isabel Ottinger is Team Head Pharmaceutical Development for Novel Biologic Entities (NBE) Early Phase since February 2018. With her team, she is responsible for the execution of all early phase NBE drug product development programs from first clinical dosage forms to post-POC formulations. In addition, she and her group take care about several NBE Drug Delivery programs in different therapeutic indications as LCM as well as first clinical formulation. Prior to her current role, Isabel was Team Head Pharmaceutical Development from 2014 to 2018.

Korbinian Löbmann

CSO at Zerion, Assoc. Prof. at University of Copenhagen

Korbinian Löbmann has a strong track record in pharmaceutical formulation and drug delivery. He has 9 years of experience in solid formulation and dosage form development, including preformulation, formulation, processing and manufacturing together with the relevant solid state characterization and quality control.

Lise Vanderkelen

Department Head Pharma and Microbial Services at Nelson Labs NV.

Lise Vanderkelen received her Ph.D. from the Faculty of Bioscience Engineering at the University of Leuven (Belgium) in 2012. She started at Nelson Labs Europe (formerly known as Toxikon Europe) in 2013 as study director Extractables & Leachables, focusing on parenteral applications and in 2014 she became responsible for the chemical characterization testing of medical devices (ISO 10993-18). In 2016, she became Department Head Pharma Services at Nelson Labs Europe.

Ramesh Shanmugam

Scientist II at AstraZeneca

Ramesh Shanmugam is a Scientist II in Formulation Sciences at AstraZeneca, Cambridge. Being a Pharmaceutical Boo-technologist, he has over 12+ years of broad cross-functional industrial research experiences in drug product formulation, lyophilization process development, biophysical characterization and drug product manufacturing process development for both early, late stage biologics.

Sabine Hauck

Vice President Research & Development at LEUKOCARE AG

Sabine Hauck is Vice President Research & Development at Munich-based biotech company Leukocare AG. She has experience of about 20 years in pharmaceutical development and has held various positions in the field of pharmaceutical development, quality assurance and regulatory affairs in small to midsize biotech and pharma companies respectively.

Shahid Uddin

Director of Drug Product, Formulation & Stability at Immunocore

Shahid is the Director of Drug product, formulation & stability at Immunocore, responsible for development for antibody and peptide and therapeutics, encompassing new novel formats. Shahid has supervised over 20 Ph.D. and Postdocs, and his experience involves both early stage formulation development as well as late stage development as both liquid and lyophilized presentations. His group also have experience of several types of drug delivery technologies including discovery and protein engineering.

Tudor Arvinte

Professor at University of Geneva, Switzerland, CEO of Therapeomic

Tudor Arvinte studied physics at University of Jassy, Romania, and received his Ph.D. in biophysics from University of Düsseldorf, Germany. He held numerous research positions in Europe and the USA at: Max-Planck Institute, Germany; C.N.R.S., France; Cornell University, New York; Texas A&M University; Ciba-Geigy U.K., Novartis, Switzerland. T. Arvinte worked with more than 200 biopharmaceuticals, three of his formulations reached the market, has over 90 publications and 15 patents.

Tanja Henzler

Director Liquid Formulation R&D at Merck KGaA

Tanja Henzler studied Biology in Tübingen and received her PhD in Virology at the Ruprechts Karls University Heidelberg. In 2002 she joined Merck in Darmstadt, Germany. Tanja Henzler has a focus in protein characterization and protein analytics. After evaluating new technologies for Merck Life Science she was coordinating an interdisciplinary and cross-divisional innovation project.

Tanvir Tabish

Head of Formulation Development for Gene Therapy and Protein Modalities at Takeda

Tanvir Tabish joined Takeda about three years ago and is presently the Head of Formulation Development and Characterisation; Tanvir is currently based in Vienna, Austria. His responsibilities include developing stable formulations for various Gene Therapy and protein based modalities. Prior to joining Takeda, Tanvir worked as an Associate Director, for Beaufour Ipsen, and managed a trans-national Early and Pre-Formulation Development group with members based in Paris and Boston.

Wei Tian

Director Formulation at Lonza

Wei Tian is an experienced pharmaceutical development professional and has achieved market authorization of several generic and NCE products in the EU and US. Many of these products were approved through the 505(b)2 application route, through reformulation and dosage changes.

Yasemin Karanis

Consultant, Thought Leadership at IQVIA

Yasemin is a Consultant in the European Thought Leadership team based in IQVIA’s London office. Her primary areas of focus are; trends in innovative launches as well as the oncology market with an emphasis on clinical and commercial trends.

Yasemin holds a Masters in Cancer Research and a Bachelor of Science degree in Biomedical Sciences both from Newcastle University. Prior to her role in Thought Leadership, Yasemin was part of the Real-World Insights – Global Oncology a team where she worked on the co-ordination and set-up of reports focusing on various cancers.

Slide BIOTECH PHARMA SUMMIT - PORTO / 2021 REGISTER NOW